

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2016/065409 A1

(43) International Publication Date
6 May 2016 (06.05.2016)

(51) International Patent Classification:

A61K 38/21 (2006.01) C07K 16/28 (2006.01)
A61K 39/395 (2006.01) C12N 15/21 (2006.01)
C07K 14/56 (2006.01) A61P 39/00 (2006.01)

(21) International Application Number:

PCT/AU2015/050654

(22) International Filing Date:

23 October 2015 (23.10.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2014904326 29 October 2014 (29.10.2014) AU

(71) Applicant: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD [AU/—]; Level 2, 37 Epping Road, Macquarie Park, New South Wales 2113 (AU).

(72) Inventors: BEHRENS, Collette; c/- Teva Pharmaceuticals Australia Pty Ltd, Level 2, 37 Epping Road, Macquarie Park, New South Wales 2113 (AU). DOYLE, Anthony; c/- Teva Pharmaceuticals Australia Pty Ltd, Level 2, 37 Epping Road, Macquarie Park, New South Wales 2113 (AU). CLARKE, Adam; c/- Teva Pharmaceuticals Australia Pty Ltd, Level 2, 37 Epping Road, Macquarie Park, New South Wales 2113 (AU). POLLARD, Matthew; c/- Teva Pharmaceuticals Australia Pty Ltd, Level 2, 37 Epping Road, Macquarie Park, New South Wales 2113 (AU). DOMAGALA, Teresa; c/- Teva Pharmaceuticals Aus-

tralia Pty Ltd, Level 2, 37 Epping Road, Macquarie Park, New South Wales 2113 (AU).

(74) Agent: DAVIES COLLISON CAVE; Level 15, 1 Nicholson Street, Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: INTERFERON α 2B VARIANTS

(57) Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon α 2b (IFN α 2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN α 2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN α 2b.



WO 2016/065409 A1